

Anti-BCL2 Antibody (1T504)

Product Details

Ig Type:	Mouse IgG1
Reactivity:	Human
Conjugation:	Unconjugated
Clone:	1T504
Purification:	Protein A

Applications

Verified Activity:	Anti-BCL2 mouse monoclonal antibody at 1:500 dilution. -Lane A: Raji Whole Cell Lysate. -Lane B: Jurkat Whole Cell Lysate. -Lane C: K562 Whole Cell Lysate. -Lane D: Hela Whole Cell lysate. -Lysates/proteins at 30 µg per lane. -Secondary -Rabbit Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution. -Developed using the ECL technique. -Performed under reducing conditions. -Predicted band size:26 kDa. -Observed band size:26 kDa
Application:	WB
Recommended	WB: 1:500-1:2000

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human Bcl-2 Protein (TMPY-02700)
Antigen Species:	Human
Synonyms:	PPP1R50;Bcl-2;B-cell CLL/lymphoma 2
Biology Area:	Cancer Drug Targets

Research Background

BCL2 (B-cell leukemia/lymphoma 2, N-Histidine-tagged), also known as Bcl-2, belongs to the Bcl-2 family. Bcl-2 family proteins regulate and contribute to programmed cell death or apoptosis. It is a large protein family and all members contain at least one of four BH (bcl-2 homology) domains. Certain members such as Bcl-2, Bcl-xl and Mcl1 are anti-apoptotic, whilst others are pro-apoptotic. Most Bcl-2 family members contain a C-terminal transmembrane domain that functions to target these proteins to the outer mitochondrial and other intracellular membranes. It is expressed in a variety of tissues. BCL2 blocks the apoptotic death of some cells such as lymphocytes. It also

A DRUG SCREENING EXPERT

regulates cell death by controlling the mitochondrial membrane permeability and inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants, produced by alternate splicing, differ in their C-terminal ends. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481